Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

131
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
131
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

131
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
131
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

105
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
105
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

134
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
134
Birth Control Methods01:22

Birth Control Methods

5.5K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
5.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Another step toward phenotypic characterization of hereditary dysfibrinogenemia?

Research and practice in thrombosis and haemostasis·2026
Same author

Contraceptive use in France by migration background and the role of social deprivation as a mediator: A national cross-sectional study.

Contraception·2026
Same author

A comprehensive multicenter study assessing the impact of abelacimab, asundexian and milvexian on coagulation assays.

Blood advances·2026
Same author

Pharmacologic Thromboprophylaxis in Medical Inpatients: A Systematic Review and Network Meta-Analysis.

JAMA network open·2026
Same author

Successful Treatment of Heavy Menstrual Bleeding in a Woman With Mild Haemophilia A Using Efanesoctocog Alfa.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

An Unusual Association Between Acquired Hemophilia A and Type 2 Autoimmune Pancreatitis.

Hamostaseologie·2026

Related Experiment Video

Updated: Nov 26, 2025

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.6K

[Contraception and venous thromboembolism].

Marc Blondon1, Alessandro Casini1, Pierre Fontana1

  • 1Service d'angiologie et d'hémostase, HUG, 1211 Genève 14, et Faculté de médecine, Université de Genève, 1211 Genève 4.

Revue Medicale Suisse
|December 10, 2020
PubMed
Summary
This summary is machine-generated.

Combined oral contraceptives are widely used in Europe and are linked to half of venous thromboembolism (VTE) cases in women under 50. This review examines VTE risk factors and contraceptive prescription guidelines.

More Related Videos

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

15.1K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.9K

Related Experiment Videos

Last Updated: Nov 26, 2025

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.6K
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

15.1K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.9K

Area of Science:

  • Reproductive Health
  • Thrombosis Research
  • Pharmacovigilance

Background:

  • Combined oral contraceptives (COCs) are the most prevalent contraceptive method in Europe.
  • COCs are associated with a significant proportion of venous thromboembolism (VTE) cases in women under 50.

Purpose of the Study:

  • To review determinants of VTE risk associated with oral contraceptives.
  • To summarize current contraceptive prescription recommendations.
  • To discuss the management of contraception in patients with VTE history.

Main Methods:

  • Narrative review of existing literature.
  • Analysis of VTE risk factors related to COCs and user-specific factors.
  • Synthesis of current clinical guidelines for contraceptive prescription.

Main Results:

  • VTE risk is influenced by COC type and individual user risk factors (genetic/acquired).
  • Current guidelines offer recommendations for safe contraceptive prescribing.
  • Patient counseling is crucial for managing contraception alongside VTE risk.

Conclusions:

  • Understanding VTE risk factors is essential for safe COC use.
  • Personalized contraceptive management is necessary for women with VTE risk.
  • Effective communication with patients minimizes risks of pregnancy, bleeding, and recurrent VTE.